Center for Breakthrough Medicines (CBM) Expands Contract Testing Services with the launch of the Analytical Accelerator™ for AAV Testing to Serve Growing Pipeline of Gene Therapies
prnewswire.com
news
2022-10-19 13:10:00

Platform Methods Reduce GMP Turnaround Times (TAT) by Three-fold, from 22 to 6 Weeks
KING OF PRUSSIA, Pa., Oct. 19, 2022 /PRNewswire/ -- The Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) dedicated to addressing the testing challenges associated with commercializing cell and gene therapies, announced today the launch of their Analytical Accelerator™ for AAV Testing to help gene therapy developers meet the quality domains of identity, safety, purity, potency, and stability required by the Food and Drug Administration (FDA) and global regulatory authorities.
